Human AR Stable Cell Line - HEK293

While treatment for metastatic prostate cancer involves androgen deprivation therapy (ADT), primary prostate cancer is dependent on androgen receptor (AR) signaling. The constitutively active androgen receptor splice variant, AR-V7, and its cellular involvement in castration-resistant prostate cancer were studied by the researchers using LNCaP and VCaP cell lines. After increasing AR-V7 expression to correspond with AR levels, they compared transcriptomes and isoform activity. Although the targets of the two AR types were similar, they showed different cistromes and discrete binding sites, especially close to transcription start sites. Higher isoform levels were frequently needed for novel targets than for traditional targets like PSA. Notably, unlike AR's sites enriched with FOXA1, AR-V7 exhibited a de novo binding motif resembling a half ARE. These results highlight the distinct functions of the isoforms, which may act as biomarkers or therapeutic targets in CRPC.

Figure 1. The researchers investigated the role of FOXA1 in differential gene regulation using the HEK293 AR Stable Cell Line. Methods included co-transfection of AR and FOXA1, followed by co-immunoprecipitation to assess protein interactions. Their findings underscored FOXA1's facilitation of AR isoform function, influencing gene expression in response to hormone treatments. These insights advance understanding of AR-V7 and AR mechanisms in prostate cancer progression. (Basil P, et al., 2022)